Brenus Pharma Wins the "Biotech" Trophy at the Prestigious Healthtech 2024 Awards Ceremony, Organized by France Biotech
2.4.2024 17:00:00 EEST | Business Wire | Press release
Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech. The ceremony took place on Monday, March 25th in Paris, gathering key players in the French health innovation ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402275595/en/
Biotech Award presented to Paul Bravetti (CEO Brenus Pharma) by Thierry Hulot (President of Merck Group activities in France - President of LEEM), Alain Huriez (Chariman and Managing Partner, AdBio Partners), Guillaume LAULHE (Director BD at IQVIA) (Photo: Brenus Pharma)
The jury, made up of over 70 scientific, institutional, political, industrial, and financial experts, awarded companies in the French Health-Tech industry that stood out for their creativity, imagination, and dynamism over the past two years. This is a great recognition from the French health ecosystem. (France Biotech Press Release)
This award testifies to the relevance of Brenus Pharma's mission: to restore the ability of cancer patients to fight resistant tumor cells and avoid relapses like never before. (Recording pitch)
"On behalf of the whole team, we thank all the jury members for this great distinction, as well as France Biotech for organizing this ceremony and for their crucial role as coordinator of the French health innovation ecosystem. Finally, congratulations to all the winning startups, nominees, and others who thrive and provide daily efforts for the health of patients." declares Paul BRAVETTI, CEO of Brenus Pharma.
About Brenus Pharma :
Brenus Pharma develops first-in-class proteomic-driven cell immunotherapies focused on tumor antigens for the treatment of solid tumors. Brenus has developed the STC platform (Stimulated Tumor Cells), a technological platform that mimics relapse conditions and allows the education of the patient's immune system to fight the resistance mechanisms of tumor cells.
https://www.brenus-pharma.com/ | Linkedin
About France Biotech
France Biotech, founded in 1997, is an independent association that brings together innovation entrepreneurs in healthcare and their expert partners. As a facilitator of the healthcare innovation ecosystem and a privileged interlocutor with public authorities in France and Europe, France Biotech contributes to addressing the challenges of the HealthTech sector (company financing, innovation taxation, regulatory issues, and market access, etc.) and proposing concrete solutions in terms of competitiveness and attractiveness through its committees and working groups. This is to help start-ups and SMEs in this sector to become successful international companies capable of quickly designing and developing new innovations and ultimately making them accessible to patients. France Biotech is housed at the PariSanté Campus. http://www.france-biotech.fr/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402275595/en/
Contact information
Press contact: Florence Portejoie - FP2COM | fportejoie@fp2com.fr | (+33) 06 07 76 82 83
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cessna Citation CJ3 Gen3 Achieves First Flight, Advancing Next-Generation Light Jet Toward Certification29.7.2026 19:31:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, recently achieved a key milestone as the Cessna Citation CJ3 Gen3 prototype aircraft completed its first flight, advancing the next-generation light jet toward certification. With this milestone, all three next-generation Citation light jets — the CJ4 Gen3, CJ3 Gen3 and M2 Gen3 — have entered flight testing, demonstrating continued momentum across the Cessna next-generation light jet portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729333762/en/ Cessna Citation CJ3 Gen3 achieves first flight, advancing next-generation light jet toward certification. (Photo credit: Textron Aviation) “This achievement continues the forward momentum of the CJ3 Gen3 program and reflects the discipline, innovation and commitment of this team,” said Chris Hearne, senior vice president, Engineering & Programs. “Comprehensive flight testing will now begin for this aircraft with ri
SES Launches Multi-Orbit Satellite Connectivity on LATAM Airbus, Embraer Fleet29.7.2026 18:30:00 EEST | Press release
SES, a leading space solutions company, was selected by LATAM Airlines to provide multi-orbit inflight connectivity service to its growing fleet of Airbus and Embraer aircraft, solidifying SES’s position as the top provider of multi-orbit broadband service in the Americas and around the world. “LATAM’s passengers will soon benefit from reliable, multi-orbit satellite connectivity that will provide the same fast and dependable internet access they enjoy at home no matter where or when they fly. SES’s partnerships with airlines like LATAM highlight how carriers throughout the Americas are leading the way when it comes to the most advanced connectivity. SES is a trusted partner that powers inflight connectivity,” said Mike DeMarco, SES President of Mobility. More than 60 Airbus (A320NEO and A321XLR) and Embraer aircraft (E195-E2) will be equipped with SES services in the coming years. LATAM will be the largest airline in the region to offer service using SES’s new electronically steered a
Carta Rearchitects Private Capital Operations with Plugins for Claude29.7.2026 17:01:00 EEST | Press release
Carta, the connected platform and AI-native ecosystem for private capital, today announces broad availability of its suite of Plugins for Claude following the initial launch in April 2026. With more than 1,500 companies and firms already using the plugins, Carta is changing the way private capital teams — from founders to CFOs — fundamentally operate, bringing fund administration, cap table management, and dealflow analytics directly into the spreadsheets, presentations, and workflows they already use every day. "For the last decade, private capital operation teams have been held back by a hidden tax: the constant, manual handoff of data between disconnected systems," said Henry Ward, Carta CEO. "Carta is eliminating that broken loop entirely by embedding intelligence directly into the tools teams already use. We are not waiting for an AI-native future for private capital — it is running on Carta today." Carta didn't just give Claude a pipe to its data. Carta built its private-capital
VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System29.7.2026 16:00:00 EEST | Press release
VDyne Inc. (“VDyne”), a privately held medical device company developing an innovative transcatheter tricuspid valve replacement (TTVR) system, today announced that the first patient has been enrolled and treated in the TRIVITA US IDE pivotal study of the TriNova™ system. The randomized controlled study will compare TriNova head-to-head with the commercially available Edwards EVOQUE™ TTVR system. The TRIVITA trial (NCT07516444) initiation marks a significant milestone in advancing treatment for tricuspid regurgitation (TR). The prospective, global, multicenter, randomized (1:1) controlled study is designed to evaluate the safety and effectiveness of the TriNova TTVR system in patients with severe or greater tricuspid regurgitation who are suitable for valve replacement. The study will be conducted in the US and Europe with up to 70 sites participating. The first patient was enrolled at the Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis, and tre
Grid Dynamics Accelerates Enterprise AI-Native Transformation With Workforce Certification and GAIN Platforms Rollout29.7.2026 16:00:00 EEST | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a leading provider of technology consulting, platform and product engineering, and AI-driven digital transformation services, today announced significant momentum in the adoption of its enterprise agentic AI solutions. Organizations across retail, financial services, manufacturing, CPG, and logistics industries are increasingly deploying Grid Dynamics’ agentic AI-native platforms and Forward Deployed Engineering (FDE)-led services to accelerate software delivery, improve operational efficiency, and transform business processes at scale. Grid Dynamics is widely recognized for its enterprise AI expertise and delivery capabilities across Fortune 1000 organizations. Grid Dynamics has partnership agreements with Anthropic and OpenAI to accelerate the adoption of these platforms within enterprises. By the end of October 2026, Grid Dynamics plans to have 90% of its engineers trained and certified on these platforms. Built to suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom